Bacterial-based systems for expression and purification of recombinant Lassa virus proteins of immunological relevance

Luis M Branco, Alex Matschiner, Joseph N Fair, Augustine Goba, Darryl B Sampey, Philip J Ferro, Kathleen A Cashman, Randal J Schoepp, Robert B Tesh, Daniel G Bausch, Robert F Garry and Mary C Guttieri. Virology Journal 2008 5:74.

June 30, 2016 BioFactura Publications

About BioFactura

BioFactura (Frederick MD) develops and commercializes high-value biosimilars (i.e., follow-on biologics or generic biopharmaceuticals) using its patented StableFast Biomanufacturing Platform, the optimal system for bringing these drugs to market with faster, lower cost, superior-quality manufacture. For over 10 years, BioFactura has been advancing life-saving medicines from the research bench to the patient using its innovative drug development and manufacturing technologies. Current and past programs include biodefense drugs against smallpox and Ebola, novel medicines for cancer, and low-cost/high-quality biosimilars for autoimmune and infectious diseases.